A Study to Compare the Safety and Effectiveness of Two Dosing Schedules of Lamivudine in Combination With Two Other Anti-HIV Drugs

• Status: Completed
• Trial end date: 1969-12-31

Summary

The purpose of this study is to compare the safety and effectiveness of 2 dosing schedules (once daily vs twice daily) of lamivudine (3TC) given with stavudine (d4T) and either indinavir (IDV) or nelfinavir (NFV) for 24 weeks.

• Phase: Phase 2

Details

• Lead Sponsor: Glaxo Wellcome
• Treatments: Indinavir; Lamivudine; Nelfinavir; Stavudine